CD33 Antibodies

CD33 Antibodies

Gene Name: CD33 (Cluster of Differentiation 33)

Function: CD33 is a cell surface protein belonging to the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It is primarily expressed on cells of myeloid lineage, including myeloid progenitor cells, monocytes, macrophages, dendritic cells, and granulocytes. CD33 is involved in regulating myeloid cell development, activation, and function.

Immune Regulation: CD33 plays a role in modulating immune responses, particularly in the context of myeloid cell activation and inflammation. It is involved in inhibitory signaling pathways that regulate myeloid cell activation and cytokine production. CD33 can act as an inhibitory receptor that dampens immune responses and prevents excessive inflammation.

Apoptosis: While CD33 itself does not directly induce apoptosis, dysregulation of CD33 signaling can affect myeloid cell survival and contribute to the pathogenesis of certain myeloid malignancies. Aberrant CD33 expression or function has been observed in acute myeloid leukemia (AML) and other myeloid disorders, suggesting a potential role in apoptosis regulation in these diseases.

Research Implications: Understanding the functions of CD33 is important for elucidating its roles in myeloid cell biology and immune regulation. Research on CD33 signaling pathways may have implications for the development of therapies targeting myeloid-related diseases and inflammatory disorders.

Clinical Relevance: CD33 has emerged as a therapeutic target for the treatment of acute myeloid leukemia (AML). Monoclonal antibodies targeting CD33, such as gemtuzumab ozogamicin, have been developed for the treatment of AML. These antibodies deliver cytotoxic agents directly to CD33-expressing leukemia cells, leading to cell death. Additionally, CD33-directed CAR-T cell therapies are being investigated for the treatment of CD33-positive AML.